Mizuho maintained its Outperform rating and $70.00 price target for Establishment Labs Holdings Inc . (NASDAQ: NASDAQ:ESTA), following the company’s recent announcement of FDA market clearance for its breast implants. The approval covers the Motiva SmoothSilk Ergonomix & Round implants for both primary and revision breast augmentation surgeries. This clearance is seen as a significant step in the company's progression towards a leading position in the global market.
The FDA's authorization is in line with Mizuho's expectations, which had already factored in a modest revenue projection for 2024. The firm anticipates that the Motiva implants will contribute approximately $5 million to Establishment Labs' 2024 earnings. The analyst from Mizuho believes that this development supports the company's financial model.
Looking ahead to 2025 and beyond, Mizuho forecasts a swift uptake of the Motiva implants in the United States. This optimism is based on the product's superior safety profile and the ongoing concerns related to Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL) cases linked to textured implants. The firm expects that these factors will drive rapid adoption in the U.S. market.
The analyst expressed confidence in the potential for Establishment Labs' shares to experience a re-rating of +20-25% as a result of the positive clearance event. The market clearance is anticipated to be a catalyst for the company's stock performance in the near term.
In conclusion, Mizuho's analysis suggests that Establishment Labs is well-positioned to capture significant market share and that the recent FDA clearance will positively impact the company's financial outlook and stock valuation.
In other recent news, Establishment Labs Inc. has been making significant strides. The U.S. Food and Drug Administration (FDA) has approved the company's Motiva Ergonomix and Round breast implants, marking the first new breast implant approval since 2013. This development has led BTIG to reiterate a Buy rating on ESTA, maintaining a $62.00 price target for the company's shares.
On the personnel front, Establishment Labs has strengthened its leadership team in anticipation of the product launch. Notably, Jeff Ehrhardt, formerly of Allergan (NYSE:AGN), has been appointed as the new General Manager of North America, and Fillipo Peter Caldini has been appointed as President of Establishment Labs.
Revenue projections for the United States are set at $1.1 million for the fourth quarter of 2024, with expectations of $19.3 million in 2025 and $55.8 million in 2026. Additionally, the company reported a revenue increase of 18.7%, reaching $44.1 million in the second quarter of 2024.
In analyst notes, Citi reiterated a Neutral rating on Establishment Labs' stock and initiated a 90-day Positive Catalyst Watch, particularly monitoring developments related to the FDA's decision-making process regarding Motiva. These are the recent developments in Establishment Labs' journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.